$BJDX News

Last published 1w ago

1w agoBJDXBluejay Diagnostics Announces 1-for-4 Reverse Stock SplitACCESS NewswireACTON, MA / ACCESS Newswire / October 30, 2026 / Bluejay Diagnostics, Inc. , a medical diagnostics company focused on improving patient outcomes through its
4w agoBJDXBluejay Achieves Toray Contractual Manufacturing Milestone, Advancing Supply-Chain Resilience and Commercialization ReadinessACCESS NewswireCompany Achieves Toray Contractual Milestone with Establishment of Manufacturing Site ACTON, MA / ACCESS Newswire / October 13, 2026 / Bluejay Diagnostics, Inc. ("Bluejay" or the
1mo agoBJDXBluejay Diagnostics Announces SYMON-II Clinical Dataset Details Supporting Evaluation of Mortality Risk in Sepsis and Septic ShockACCESS NewswireSYMON-II Clinical Validation Dataset Represents a Key Milestone as Bluejay Advances the Symphony™ IL-6 Test Toward Regulatory Submission ACTON, MA / ACCESS Newswire / October 6, 2026 / Bluejay Diagnostics, Inc.
2mo agoBJDXBluejay Diagnostics and Lovell Government Services Announce Partnership to Expand Access to U.S. Federal Healthcare MarketsGlobeNewswireACTON, Mass. and PENSACOLA, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient
3mo agoBJDXBluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphony™ IL-6 Toward Regulatory Submission and CommercializationGlobeNewswireSYMON-II pivotal clinical study completes targeted enrollment of 750 patientsCompany advances toward planned 510(k) submission and commercialization with US manufacturing contract signed to mitigate supply-chain
3mo agoBJDXBluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation StudyGlobeNewswireACTON, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), a medical diagnostics company developing rapid, near-patient diagnostic technologies for critical care, today announced the
5mo agoBJDXBluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswire$8.5 million upfront with up to approximately $15.2 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond
5mo agoBJDXBluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswire$8.5 million upfront with up to approximately $15.1 million of potential additional gross proceeds upon the exercise in full of warrants Net proceeds anticipated to extend cash runway into first quarter of 2027, beyond
5mo agoBJDXBluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic PartnershipGlobeNewswireACTON, Mass. and CARLSBAD, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company") (NASDAQ:BJDX), a medical diagnostics company focused on near-patient testing for critical
6mo agoBJDXBluejay Diagnostics Provides First Quarter 2026 Corporate UpdateGlobeNewswireACTON, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on improving patient outcomes in critical care settings, today provided a
7mo agoBJDXBluejay Diagnostics, Inc. Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical TrialGlobeNewswireACTON, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. ("Bluejay" or the "Company"), a medical diagnostics company focused on rapid, near-patient testing, today announced the successful enrollment
8mo agoBJDXBluejay Diagnostics Provides Corporate Update and 2026 Strategic OutlookGlobeNewswireACTON, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient tests to improve patient outcomes in
8mo agoBJDXBluejay Diagnostics Announces All Prefunded Warrants Now ExercisedGlobeNewswireACTON, Mass., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that as of February 19, 2026, all of the prefunded warrants issued by the Company in its October 2025 private placement
8mo agoBJDXBluejay Diagnostics Successfully Enrolls 545 Patients in SYMON™ II Study and Advances Manufacturing Readiness into 2026GlobeNewswireACTON, Mass., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics (NASDAQ:BJDX) today announced that it has successfully enrolled 545 patients in its SYMON™ II multicenter clinical study and has made
9mo agoBJDXBluejay Diagnostics Announces 1-for-4 Reverse Stock SplitGlobeNewswireACTON, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
10mo agoBJDXBluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody ProductionGlobeNewswireACTON, Mass., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company") announced that it has completed commercial-scale production of both polyclonal and monoclonal
1y agoBJDXBluejay Diagnostics Corporate Update: Advancing Clinical Milestones and Strategic PartnershipsGlobeNewswireCompany focused on advancing clinical milestones and strategic partnerships, with goal of positioning itself for future FDA clearance and product commercialization.Patient enrollment in SYMON-II clinical trial now
1y agoBJDXBluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq RulesGlobeNewswireACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient solutions for critical care, today announced
1y agoBJDXBluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq RulesGlobeNewswireACTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient solutions for critical care, today announced
1y agoBJDXBluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony PlatformGlobeNewswireACTON, Mass. and YAMANASHI, Japan, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay"), a medical diagnostics company focused on developing rapid near-patient testing solutions for
1y agoBJDXBluejay Diagnostics Provides Second Quarter Business and Corporate UpdateGlobeNewswireACTON, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing near-patient solutions for critical care, today announced
1y agoBJDXBluejay Diagnostics Provides Mid-Year Business and Corporate UpdateGlobeNewswireACTON, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid near-patient testing solutions for critical care,
1y agoBJDXBluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual MeetingGlobeNewswireACTON, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced acceptance of an abstract related to the Symphony IL-6 Test, the company's lead product candidate, for
1y agoBJDXBluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross ProceedsGlobeNewswireACTON, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
1y agoBJDXBluejay Diagnostics Announces Reverse Stock SplitGlobeNewswireACTON, Mass., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
2y agoBJDXBluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public OfferingGlobeNewswireACTON, Mass., June 28, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
2y agoBJDXBluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public OfferingGlobeNewswireACTON, Mass., June 27, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
2y agoBJDXSYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis PatientsGlobeNewswireACTON, Mass., June 26, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX), today announced results from the primary analysis of SYMON-I, a multicenter pilot clinical study investigating the role of
2y agoBJDXBluejay Diagnostics Announces Reverse Stock SplitGlobeNewswireACTON, Mass., June 17, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
2y agoBJDXBluejay Diagnostics Announces Closing of $3.5 Million Public OfferingGlobeNewswireACTON, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
2y agoBJDXBluejay Diagnostics Announces Pricing of $3.5 Million Public OfferingGlobeNewswireACTON, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
2y agoBJDXBluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)GlobeNewswireThis Study performs unique rapid on-site measurements of interleukin-6 (IL-6) and positions Company to move forward with multiple initiatives. ACTON, Mass., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc.
3y agoBJDXBluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial ResultsGlobeNewswireACTON, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood
3y agoBJDXBluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesGlobeNewswireACTON, Mass., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
3y agoBJDXBluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsGlobeNewswireACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
3y agoBJDXBluejay Diagnostics Announces Reverse Stock SplitGlobeNewswireACTON, Mass., July 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
3y agoBJDXBluejay Diagnostics Updates Symphony IL-6 Regulatory StrategyGlobeNewswireACTON, Mass., May 19, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical technology company developing rapid diagnostics on its Symphony platform to improve
3y agoBJDXBluejay Diagnostics Reports First Quarter 2023 Financial ResultsGlobeNewswireACTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to
3y agoBJDXBluejay Diagnostics Reports 2022 Financial ResultsGlobeNewswireACTON, Mass., March 20, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company developing rapid tests using whole blood on its Symphony platform to
3y agoBJDXBluejay Diagnostics Signs Collaboration Agreement with Blood Centers of AmericaGlobeNewswireACTON, Mass. and WEST WARWICK, R.I., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay"), and Blood Centers of America (BCA) today announced that they have executed a collaborative
4y agoBJDXBluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial ResultsGlobeNewswireACTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a clinical-stage medical diagnostics company developing rapid, near-patient tests using whole blood
4y agoBJDXBluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireACTON, Mass., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease progr
4y agoBJDXBluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory FailureGlobeNewswireACTON, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease pro
4y agoBJDXPositive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022GlobeNewswireDemonstrated 98% NPV1 to Identify COVID-19 Patients at Risk for Severe Illness Study Data Indicate Symphony IL-6 Test Could be a Rapid and Precise Diagnostic Platform for Near-Patient Management of Critical Care ACTON, Mass., July 27, 2022 (GLO
4y agoBJDXBluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial ResultsGlobeNewswireACTON, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay" or the "Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient tests for triage and monitoring of disease pro
4y agoBJDXBluejay Completes Planned Clinical Studies for Symphony IL-6 TestGlobeNewswireACTON, Mass., July 06, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease pr
4y agoBJDXBluejay Reports FDA Agrees to Consider its Plan to Pursue a De Novo Regulatory Pathway for the Symphony IL-6 TestGlobeNewswireACTON, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company"), a medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring of disease pr
4y agoBJDXBluejay Diagnostics, Inc. Reports First Quarter 2022 Financial ResultsGlobeNewswireACTON, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company"), a pre-revenue medical diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitoring
4y agoBJDXBluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and ComplianceGlobeNewswireACTON, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company") a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitori
4y agoBJDXBluejay Diagnostics Appoints Kenneth Fisher as Chief Financial OfficerGlobeNewswireACTON, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ:BJDX) ("Bluejay", "the Company"), a late-stage, pre-revenue diagnostics company focused on developing cost-effective, rapid, near-patient products for triage and monitor